Cetuximab after bevacizumab in metastatic colorectal cancer: Is it the best sequence?

Digestive and Liver Disease

Volumn 43, Issue 11, 2011, Pages 917-919

  Norguet, Emmanuelle ^a   Dahan, Laetitia ^a   Gaudart, Jean ^c   Gasmi, Mohamed ^b   Ouafik, L'houcine ^c   Seitz, Jean François ^a  

^a TIMONE HOSPITAL   (France)

^b HÔPITAL NORD   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Bevacizumab; Cetuximab; Colorectal cancer

Indexed keywords

BEVACIZUMAB; CETUXIMAB; DNA; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; METASTATIC COLORECTAL CANCER; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; GENES, RAS; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; PYRIDINES; TREATMENT FAILURE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052928579     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2011.06.002     Document Type: Article

References (12)

1. Hecht J.R., Mitchell E., Chidiac T., et al. Randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009, 27:672-680.
2. Tol J., Koopman M., Cats A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360:563-572.
3. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
4. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
5. Jonker D.J., O'Callaghan, Karapetis C.S., et al. Cetuximab for the treatment of colorectal cancer. N Eng J Med 2007, 357:2040-2048.
6. Sobrero A.F., Maurel J., Fehrenbacher L., et al. EPIC: Phase III. Trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:2311-2319.
7. Ellis L.M. Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am 2004, 18:1007-1021.
8. Viloria-Petit A., Crombet T., Jothy S., et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001, 61:5090-5101.
9. Ciardiello F., Bianco R., Caputo R., et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004, 10:784-793.
10. Mutsaers A.J., Francia G., Man S., et al. Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent. Clin Cancer Res 2009, 15:2397-2405.
11. Vincenzi B., Santini D., Russo A., et al. reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. Pharmacogenomics 2007, 8:319-327.
12. Crawford Y., Kasman I., Yu L., et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009, 15:21-34.